GENE ONLINE|News &
Opinion
Blog

2022-12-14| In-DepthSpecial

A Force To Be Reckoned With – BioBetter Biologics

by GeneOnline
Share To
Off-patent biologics are a large market for ‘follow-on’ biologics. Biobetters, in particular, are novel innovations designed to be therapeutically more efficient and safer. They present a new market territory and have witnessed growing interest among drug manufacturers in recent years.

The marketing term ‘biobetter’ was coined in a Mumbai bio-conference in 2007 by Mr. GV Prasa, an Indian business executive, and has been markedly used ever since. Biobetters are novel highly-differentiated entities with strong bio-superiority over existing approved biologics. They are the result of cutting-edge research and novel chemical/molecular modifications (e.g. PEGylation/residue substitutions), and boast enhanced therapeutic benefits, such as improved potency and selectivity, increased bioavailability, longer half-life, and better safety.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top